| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 199.6 | 166.8 | 166.7 |
| Other income | 4.2 | 2.5 | 5.7 |
| Total income | 203.8 | 169.3 | 172.4 |
| Profit before exceptional items & tax | 0.8 | -4.0 | -4.8 |
| Exceptional items | 2.7 | 2.7 | 11.3 |
| Profit before tax | 3.6 | -1.2 | 6.6 |
| Net profit | 2.2 | -1.0 | 4.0 |
| Operating margin | 1.8% | -0.7% | 3.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.00% |
|---|---|
| Revenue, year on year | +19.70% |
| Operating profit, year on year | +67.60% |
| Operating profit, quarter on quarter | +47.70% |
NSE results filing, NSE: PANACEABIO. Figures extracted from the filing.
Panacea Biotec Ltd: key numbers
- Share price
- ₹372.60
- Market cap
- ₹2,282 Cr
- Revenue (annual)
- ₹639.8 Cr
- Net profit (annual)
- ₹-5.37 Cr
- P/E (TTM)
- -320.5×Sector 50.4×
- Promoter holding
- 72.48%+0.00% QoQ
- FII holding
- 2.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Panacea Biotec Ltd
All →Panacea Biotec Legal & Regulatory
Panacea Biotec received four income tax demand orders totaling ₹9.82 Crore for alleged misreporting. The company contests this as non-maintainable and plans to appeal.
- Value
- ₹9.82 Cr
Panacea Biotec Other Announcement
Panacea Biotec sent reminder letters to physical shareholders requesting PAN and KYC updates per SEBI circulars. No transaction or business event is involved.
Panacea Biotec Annual General Meeting
Panacea Biotec Limited issued the notice for its 42nd Annual General Meeting scheduled for September 29, 2026, via video conferencing. Shareholders can participate through remote e-voting.
Panacea Biotec Other Announcement
Panacea Biotec Limited has submitted its monthly share dematerialization report for August 2026. This is a routine regulatory compliance filing under SEBI Regulation 74(5).
Panacea Biotec Q4 FY26 Results: Net Loss of ₹1 Cr, Loss Narrows
Panacea Biotec Ltd reported revenue from operations of ₹166.8 Cr (+25.9% YoY) and a net loss of ₹1 Cr for Q4 FY26.
- Key figure
- Net loss ₹1 Cr